CD5 Plus data

XOMA presented data from a three-year, single-center Phase III trial in patients who had received allogeneic marrow transplants. CD5 Plus failed to demonstrate a statistically significant difference from placebo at the primary end point of complete remission (CR) in GvHD at day 43.

CR at day 43 was 44 percent in the treatment group and 37 percent in the placebo group (p=0.36). CR at day 29, a secondary end point, was 40 percent in the treatment group and 25 percent in the placebo group (p=0.019). ...